- Home
- CRBP vs BEBE Comparison
CRBP vs BEBE Comparison
Compare CRBP & BEBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | BEBE |
|---|---|---|
| Founded | 2009 | 2025 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 198.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBP | BEBE |
|---|---|---|
| Price | $7.84 | $9.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $45.50 | N/A |
| AVG Volume (30 Days) | ★ 669.6K | 9.2K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $116.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $6.73 | $9.81 |
| 52 Week High | $20.56 | $9.95 |
Technical Indicators
Market Signals| Indicator | CRBP | BEBE |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 66.27 |
| Support Level | $7.62 | $9.90 |
| Resistance Level | $8.54 | N/A |
| Average True Range (ATR) | 0.66 | 0.01 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 11.37 | 100.00 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About BEBE TGE Value Creative Solutions Corp Class A Ordinary Shares
TGE Value Creative Solutions Corp is a blank check company.